The Absorb bioresorbable vascular scaffold in real-world practice: long-term follow-up of the AMC Single Centre Real World PCI Registry
| Autor: | R. J. de Winter, Jan J. Piek, Joanna J. Wykrzykowska, Robin P. Kraak, J. Baan, Ruben Y.G. Tijssen, Marcel A.M. Beijk, M. E. Annink, M.M. Vis, Karel T. Koch, José P.S. Henriques |
|---|---|
| Přispěvatelé: | Cardiology, ACS - Atherosclerosis & ischemic syndromes, APH - Aging & Later Life, ACS - Pulmonary hypertension & thrombosis, ACS - Heart failure & arrhythmias, ACS - Microcirculation, VU University medical center |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
education.field_of_study business.industry Population Target-vessel failure medicine.disease Thrombosis Surgery Single centre Cohort Conventional PCI Scaffold thrombosis medicine Bioresorbable scaffolds Original Article Myocardial infarction Cardiology and Cardiovascular Medicine business education Bioresorbable scaffold Bioresorbable vascular scaffold |
| Zdroj: | Netherlands Heart Journal Tijssen, R Y G, Annink, M E, Kraak, R P, Koch, K T, Baan, J, Vis, M M, Piek, J J, Henriques, J P S, de Winter, R J, Beijk, M A M & Wykrzykowska, J J 2020, ' The Absorb bioresorbable vascular scaffold in real-world practice : long-term follow-up of the AMC Single Centre Real World PCI Registry ', Netherlands Heart Journal, vol. 28, no. 3, pp. 153-160 . https://doi.org/10.1007/s12471-019-01362-4 Netherlands heart journal, 28(3), 153-160. Bohn Stafleu van Loghum Netherlands Heart Journal, 28(3), 153-160. Bohn Stafleu van Loghum |
| ISSN: | 1568-5888 |
| Popis: | Background Bioresorbable scaffolds have been introduced to overcome the shortcomings of drug-eluting stents. Higher rates of device thrombosis, however, have been reported up to 3 years after implantation of the Absorb bioresorbable vascular scaffold (BVS). In the current article, we therefore report long-term clinical outcomes of the AMC Absorb Registry. Methods and results In the AMC Absorb Registry, all patients who underwent a percutaneous coronary intervention with Absorb BVS implantation between 30 August 2012 and 5 August 2013 at the Amsterdam University Medical Centre—Academic Medical Centre were included. The composite endpoint of this analysis was target-vessel failure (TVF). The median follow-up of the study cohort of the AMC Absorb Registry was 1534 days. At the time of the cross-sectional data sweep the clinical status at 4 years was known in 124 of 135 patients (91.9%). At long-term follow-up, the composite endpoint of TVF had occurred in 27 patients. The 4‑year Kaplan-Meier estimate of TVF was 19.8%. At 4 years cardiac death had occurred in 4 patients (3.2%) and target-vessel myocardial infarction in 9 (6.9%) patients. Definite scaffold thrombosis occurred in 5 (3.8%) patients. We found 1 case of very late scaffold thrombosis that occurred at 911 days after device implantation in a patient who was not on dual anti-platelet therapy. Conclusion In a patient population reflecting routine clinical practice, we found that cases of TVF continued to accrue beyond 2 years after Absorb BVS implantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink